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Abstract
The asymmetric Hopfield model is used to simulate signaling dynamics in gene regulatory networks.
The model allows for a direct mapping of a gene expression pattern into attractor states. We analyze
different control strategies aimed at disrupting attractor patterns using selective local fields representing
therapeutic interventions. The control strategies are based on the identification of signaling bottlenecks,
which are single nodes or strongly connected clusters of nodes that have a large impact on the signaling.
We provide a theorem with bounds on the minimum number of nodes that guarantee control of bottlenecks
consisting of strongly connected components. The control strategies are applied to the identification of
sets of proteins that, when inhibited, selectively disrupt the signaling of cancer cells while preserving
the signaling of normal cells. We use an experimentally validated non-specific and an algorithmically-
assembled specific B cell gene regulatory network reconstructed from gene expression data to model
cancer signaling in lung and B cells, respectively. This model could help in the rational design of novel
robust therapeutic interventions based on our increasing knowledge of complex gene signaling networks.
Introduction
The vision behind systems biology is that complex interactions and emergent properties determine the
behavior of biological systems. Many theoretical tools developed in the framework of spin glass models are
well suited to describe emergent properties, and their application to large biological networks represents
an approach that goes beyond pinpointing the behavior of a few genes or metabolites in a pathway. The
2Hopfield model [35] is a spin glass model that was introduced to describe neural networks, and that is
solvable using mean field theory [6]. The asymmetric case, in which the interaction between the spins
can be seen as directed, can also be exacty solved in some limits [23]. The model belongs to the class of
attractor neural networks, in which the spins evolve towards stored attractor patterns, and it has been
used to model biological processes of high current interest, such as the reprogramming of pluripotent
stem cells [42]. Moreover, it has been suggested that a biological system in a chronic or therapy-resistant
disease state can be seen as a network that has become trapped in a pathological Hopfield attractor [7]. A
similar class of models is represented by Random Boolean Networks [4], which were proposed by Kauffman
to describe gene regulation and expression states in cells [38]. Differences and similarities between the
Kauffman-type and Hopfield-type random networks have been studied for many years [5, 40, 41, 57].
In this paper, we consider an asymmetric Hopfield model built from real (even if incomplete [22, 34])
cellular networks, and we map the spin attractor states to gene expression data from normal and cancer
cells. We will focus on the question of controling of a network’s final state (after a transient period) using
external local fields representing therapeutic interventions. To a major extent, the final determinant of
cellular phenotype is the expression and activity pattern of all proteins within the cell, which is related to
levels of mRNA transcripts. Microarrays measure genome-wide levels of mRNA expression that therefore
can be considered a rough snapshot of the state of the cell. This state is relatively stable, reproducible,
unique to cell types, and can differentiate cancer cells from normal cells, as well as differentiate between
different types of cancer [13, 25]. In fact, there is evidence that attractors exist in gene expression
states, and that these attractors can be reached by different trajectories rather than only by a single
transcriptional program [36]. While the dynamical attractors paradigm has been originally proposed in
the context of cellular developement, the similarity between cellular ontogenesis, i.e. the developement of
different cell types, and oncogenesis, i.e. the process under which normal cells are transformed into cancer
cells, has been recently emphasized [64]. The main hypothesis of this paper is that cancer robustness
is rooted in the dynamical robustness of signaling in an underlying cellular network. If the cancerous
state of rapid, uncontrolled growth is an attractor state of the system [8], a goal of modeling therapeutic
control could be to design complex therapeutic interventions based on drug combinations [29] that push
the cell out of the cancer attractor basin [19].
Many authors have discussed the control of biological signaling networks using complex external
perturbations. Calzolari and coworkers considered the effect of complex external signals on apoptosis
3signaling [14]. Agoston and coworkers [1] suggested that perturbing a complex biological network with
partial inhibition of many targets could be more effective than the complete inhibition of a single target,
and explicitly discussed the implications for multi-drug therapies [20]. In the traditional approach to
control theory [62], the control of a dynamical system consists in finding the specific input temporal
sequence required to drive the system to a desired output. This approach has been discussed in the context
of Kauffmann Boolean networks [3] and their attractor states [15]. Several studies have focused on the
intrinsic global properties of control and hierarchical organization in biological networks [12,28]. A recent
study has focused on the minimum number of nodes that needs to be addressed to achieve the complete
control of a network [45]. This study used a linear control framework, a matching algorithm [55] to find
the minimum number of controllers, and a replica method to provide an analytic formulation consistent
with the numerical study. Finally, Cornelius et al. [18] discussed how nonlinearity in network signaling
allows reprogrammig a system to a desired attractor state even in the presence of contraints in the nodes
that can be accessed by external control. This novel concept was explicitly applied to a T-cell survival
signaling network to identify potential drug targets in T-LGL leukemia. The approach in the present
paper is based on nonlinear signaling rules and takes advantage of some useful properties of the Hopfield
formulation. In particular, by considering two attractor states we will show that the network separates
into two types of domains which do not interact with each other. Moreover, the Hopfield framework
allows for a direct mapping of a gene expression pattern into an attractor state of the signaling dynamics,
facilitating the integration of genomic data in the modeling.
The paper is structured as follows. In Mathematical Model we summarize the model and review some
of its key properties. Control Strategies describes general strategies aiming at selectively disrupting the
signaling only in cells that are near a cancer attractor state. The strategies we have investigated use the
concept of bottlenecks, which identify single nodes or strongly connected clusters of nodes that have a large
impact on the signaling. In this section we also provide a theorem with bounds on the minimum number of
nodes that guarantee control of a bottleneck consisting of a strongly connected component. This theorem
is useful for practical applications since it helps to establish whether an exhaustive search for such minimal
set of nodes is practical. In Cancer Signaling we apply the methods from Control Strategies to lung and B
cell cancers. We use two different networks for this analysis. The first is an experimentally validated and
non-specific network (that is, the observed interactions are compiled from many experiments conducted on
heterogeneous cell types) obtained from a kinase interactome and phospho-protein database [72] combined
4with a database of interactions between transcription factors and their target genes [47]. The second
network is cell-specific and was obtained using network reconstruction algorithms and transcriptional
and post-translational data from mature human B cells [43]. The algorithmically reconstructed network
is significantly more dense than the experimental one, and the same control strategies produce different
results in the two cases. Finally, we close with Conclusions.
Methods
Mathematical Model
We define the adjacency matrix of a network G composed of N nodes as
Aij =


1 if j → i
0 otherwise
, (1)
where j → i denotes a directed edge from node j to node i. The set of nodes in the network G is indicated
by V (G) and the set of directed edges is indicated by E(G) = {(j, i) : j → i}. (See Table 1 for a list of
mathematical symbols used in the text.) The spin of node i at time t is σi(t) = ±1, and indicates an
expresssed (+1) or not expressed (−1) gene. We encode an arbitrary attractor state ~ξ = (ξ1, ξ2, ..., ξN )
with ξi = ±1 by defining the coupling matrix [35]
Jij = Aijξiξj . (2)
The total field at node i is then hi = h
ext
i +
∑
j Jijσj , where h
ext
i is the external field applied to node i,
which will be discussed below. The discrete-time update scheme is defined as
σi(t+∆t) =


+1 with prob. (1 + exp[−hi(t)/T ])
−1
−1 with prob. (1 + exp[+hi(t)/T ])
−1
(3)
where T ≥ 0 is an effective temperature. For the remainder of the paper, we consider the case of T = 0
so that σi = sign(hi), and the spin is chosen randomly from ±1 if hi = 0. For convenience, we take
t ∈ Z and ∆t = 1. Nodes can be updated synchronously, and synchronous updating can lead to limit
5cycles [57]. Nodes can also be updated separately and in random order (anynchronous updating), which
does not result in limit cycles. All results presented in this paper use the synchronous update scheme.
Source nodes (nodes with zero indegree) are fixed to their initial states by a small external field so
that σq(t) = σq(0) for all q ∈ Q, where Q is the set of source nodes. However, the source nodes flip if
directly targeted by an external field. Biologically, genes at the “top” of a network are assumed to be
controlled by elements outside of the network.
In application, two attractors are needed. Define these states as ~ξn and ~ξc, the normal state and
cancer state, respectively. The magnetization along attractor state a is
ma(t) =
1
N
N∑
i=1
σi(t)ξ
a
i . (4)
Note that if ma(t) = ±1, ~σ(t) = ±~ξa. We also define the steady state magnetization along state a as
ma
∞
= lim
τ→∞
1
τ
τ∑
t=1
ma(t) . (5)
There are two ways to model normal and cancer cells. One way is to simply define a different coupling
matrix for each attractor state a,
Jaij = Aijξ
a
i ξ
a
j . (6)
Alternatively, both attractor states can be encoded in the same coupling matrix,
Jij = Aij(ξ
n
i ξ
n
j + ξ
c
i ξ
c
j ) . (7)
Systems using Eqs. 6 and 7 will be referred to as the one attractor state (p = 1) and two attractor state
(p = 2) systems, respectively. Eqs. 6 and 7 are particular cases of the general Hopfield form [35]
Jij = Aij
p∑
k=1
ξki ξ
k
j , (8)
where p is the number of attractor states, often taken to be large. An interesting property emerges when
p = 2, however. Consider a simple network composed of two nodes, with only one edge 1 → 2 with
6attractor states ~ξn and ~ξc, and T = 0. The only nonzero entry of the matrix Jij is
J21 = ξ
n
2 ξ
n
1 + ξ
c
2ξ
c
1 . (9)
Note that if ~ξn = ±~ξc, J21 = 2ξ
n
2 ξ
n
1 . In either case, by Eq. 3 we have
σ2(t+ 1) =


+ξn2 if σ1(t) = +ξ
n
1
−ξn2 if σ1(t) = −ξ
n
1
, (10)
that is, the spin of node 2 at a given time step will be driven to match the attractor state of node 1 at
the previous time step. However, if ξn1 = ±ξ
c
1 and ξ
n
2 = ∓ξ
c
2, J21 = 0. This gives
σ2(t) =


+1 with probability 1/2
−1 with probability 1/2
(11)
In this case, node 2 receives no input from node 1. Nodes 1 and 2 have become effectively disconnected.
This motivates new designations for node types. We define similarity nodes as nodes with ξni = ξ
c
i ,
and differential nodes as nodes with ξni = −ξ
c
i . We also define the set of similarity nodes S = {i : ξ
n
i = ξ
c
i }
and the set of differential nodes D = {i : ξni = −ξ
c
i }. Connections between two similarity nodes or two
differential nodes remain in the network, whereas connections that link nodes of different types transmit
no signals. The effective deletion of edges between nodes means that the original network fully separates
into two subnetworks: one composed entirely of similarity nodes (the similarity network) and another
composed entirely of differential nodes (the differential network), each of which can be composed of one
or more separate weakly connected components (see Fig. 1). With this separation, new source nodes
(effective sources) can be exposed in both the similarity and differential networks. For the remainder of
this article, Q is the set of both source and effective source nodes in a given network.
Control Strategies
The strategies presented below focus on selecting the best single nodes or small clusters of nodes to
control, ranked by how much they individually change ma
∞
. In application, however, controlling many
nodes is necessary to achieve a sufficiently changed ma
∞
. The effects of controlling a set of nodes can
7be more than the sum of the effects of controlling individual nodes, and predicting the truly optimal set
of nodes to target is computationally difficult. Here, we discuss heuristic strategies for controlling large
networks where the combinatorial approach is impractical.
For both p = 1 and p = 2, simulating a cancer cell means that ~σ(0) = +~ξc, and likewise for normal
cells. Although the normal and cancer states are mathematically interchangeable, biologically we seek to
decrease mc
∞
as much as possible while leaving mn
∞
≈ +1. By “network control” we thus mean driving
the system away from its initial state of ~σ(0) = ~ξc with ~hext. Controlling individual nodes is achieved by
applying a strong field (stronger than the magnitude of the field due to the node’s upstream neighbors)
to a set of targeted nodes T so that
hextτ =


lim(u→∞)−uξ
c
τ τ ∈ T
0 else
. (12)
This ensures that the drug field can always overcome the field from neighboring nodes.
In application, similarity nodes are never deliberately directly targeted, since changing their state
would adversely affect both normal and cancer cells. Roughly 70% of the nodes in the networks surveyed
are similarity nodes, so the search space is reduced. For p = 2, the effective edge deletion means that
only the differential network in cancer cells needs to be simulated to determine the effectiveness of ~hext.
For p = 1, however, there may be some similarity nodes that receive signals from upstream differential
nodes. In this case, the full effect of ~hext can be determined only by simulating all differential nodes as
well as any similarity nodes downstream of differential nodes. All following discussion assumes that all
nodes examined are differential, and therefore targetable, for both p = 1 and p = 2. The existence of
similarity nodes for p = 1 only limits the set of targetable nodes.
Directed acyclic networks
Full control of a directed acyclic network is achieved by forcing σq = −ξ
c
q for all q ∈ Q. This guarantees
mc
∞
= −1. Suppose that nodes q ∈ Q in an acyclic network have always been fixed away from the cancer
state, that is, σq(t→ −∞) = −ξ
c
q. For any node i to have σi(t) = ξ
n
i , it is sufficient to have either i ∈ Q
or σj(t− 1) = ξ
n
j for all j → i, i /∈ Q. Because there are no cycles present, all upstream paths of sufficent
length terminate at a source. Because the spin of all nodes q ∈ Q point away from the cancer attractor
state, all nodes downstream must also point away from the cancer attractor state. Thus, for acyclic
8networks, forcing σq = −ξ
c
q guarantees m
c
∞
= −1. The complications that arise from cycles are discussed
in the next subsubsection. However, controlling nodes in Q may not be the most efficient way to push
the system away from the cancer basin of attraction and, depending on the control limitations, it may
not be possible. If minimizing the number of controllers is required, searching for the most important
bottlenecks is a better strategy.
Consider a directed network G and an initially identical copy, G′ = G. If removing node i (and all
connections to and from i) from G′ decreases the indegree of at least one node j ∈ V (G′), j 6= i, to less
than half of its indegree in network G, {i} is a size 1 bottleneck. The bottleneck control set of bottleneck
{i}, L(i), is defined algorithmically as follows: (1) Begin a set L(i) with the current bottleneck i so that
L = {i}; (2) Remove bottleneck {i} from network G′; (3) Append L(i) with all nodes j with current
indegree that is less than half of that from the original network G; (4) Remove all nodes j from the
network G′. If additional nodes in G′ have their indegree reduced to below half of their indegree in G,
go to step 3. Otherwise, stop. The impact of the bottleneck i, I(i), is defined as
I(i) = |L(i)| , (13)
where |X | is the cardinality of the set X . The impact of a bottleneck is the minimum number of nodes
that are guaranteed to switch away from the cancer state when the bottleneck is forced away from the
cancer state.
The impact is used to rank the size 1 bottlenecks by importance, with the most important as those
with the largest impact. In application, when searching for nodes to control, any size 1 bottleneck {i}
that appears in the bottleneck control set of a different size 1 bottleneck {j} can be ignored, since fixing
j to the normal state fixes i to the normal state as well. Note that the definition given above in terms of
G and G′ avoids miscounting in the impact of a bottleneck.
The network in Fig. 2, for example, has three sources (nodes 1, 2 and 3), but one important bottleneck
(node 6). If full damage, i.e. mc
∞
= −1, is required, then control of all source nodes is necessary. If
minimizing the number of directly targeted nodes is important and mc
∞
> −1 can be tolerated, then
control of the bottleneck node 6 is a better choice.
9Directed cycle-rich networks
Not all networks can be fully controlled at T = 0 by controlling the source nodes, however. If there
is a cycle present, paths of infinite length exist and the final state of the system may depend on the
initial state, causing parts of the network to be hysteretic. Controlling only sources in a general directed
network thus does not guarantee mc
∞
= −1 unless the system begins with σi = −ξ
c
i .
Define a cycle cluster, C, as a strongly connected subnetwork of a network G. The network in Fig. 3,
for example, has one cycle cluster with nodes V (C) = {4, 5, 6, 7}. If the network begins with ~σ(0) = ~ξc,
forcing both source nodes away from the cancer state does nothing to the nodes downsteam of node 3
(see Fig. 4). This is because the indegree deg−(4) = 4, and a majority of the nodes connecting to node 4
are in the cancer attractor state. At T = 0, cycle clusters with high connectivity tend to block incoming
signals from outside of the cluster, resulting in an insurmountable activation barrier.
The most effective single node to control in this network is any one of nodes 4, 6 or 7. Forcing any of
these away from the cancer attractor state will eventually cause the entire cycle cluster to flip away from
the cancer state, and all nodes downstream will flip as well, as shown in Fig. 4. The cycle cluster here
acts as a sort of large, hysteretic bottleneck. We now generalize the concept of bottlenecks.
Define a size k bottleneck in a network G to be a cycle cluster B with |V (B)| = k which, when removed
from G, reduces the indegree of at least one node j ∈ V (G), j 6∈ V (B) to less than half of its original
indegree. Other than now using the set of nodes V (B) rather than a single node set, the above algorithm
for finding the bottleneck control set remains unchanged. In Fig. 3, for instance, V (B) = {4, 5, 6, 7},
k = 4, L(B) = {4, 5, 6, 7, 8, 9, 10}, and I(B) = 7. With this more general definition, we note that
controlling any size k bottleneck B guarantees control of all size 1 bottlenecks B′ in the control set of B
for all k ≥ 1.
For any bottleneck B of size k ≥ 1 in a networkG, define the set of critical nodes, Z(B,G), as the set of
nodes Z(B,G) ⊆ V (B) of minimum cardinality that, when controlled, guarantees full control of all nodes
i ∈ V (B) after a transient period. Also define the critical number of nodes as ncrit(B,G) = |Z(B,G)|.
Thus, for the network in Fig. 3, Z(B,G) = {4}, {6}, or {7}, and ncrit(B,G) = 1.
In general, however, more than one node in a cycle cluster may need to be targeted to control the
entire cycle cluster. Fig. 5 shows a cycle cluster (composed of nodes 2-10) that cannot be controlled by
targeting any single node. The precise value of ncrit for a given cycle cluster C depends on its topology
as well as the edges connecting nodes from outside of C to the nodes inside of C, and finding Z(C,G)
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can be difficult. We present a theorem that puts bounds on ncrit to help determine whether a search for
Z(C,G) is practical.
Theorem: Suppose a network G contains a cycle cluster C. Define the set of externally influenced
nodes
R(C,G) = {i ∈ V (C) : j ∈ V (G \ C), (j, i) ∈ E(G)} , (14)
the set of intruder connections
W (C,G) = {(j, i) ∈ E(G) : i ∈ V (C), j ∈ V (G \ C)} , (15)
and the reduced set of critical nodes
Zred(C,G) = Z(C,G \W ) . (16)
If N = |V (C)| and
µ ≡ min
i∈V (C)
deg−(i) , (17)
where deg−(i) is computed ignoring intruder connections, then
⌈µ
2
⌉
≤ ncrit(C,G) ≤ ζ , (18)
where
ζ ≡ min
(⌈
N
2
⌉
+ |R(C,G) \ Zred(C,G)|, N
)
. (19)
Proof: First, prove the lower limit of Eq. 18. Let C be a cycle cluster in a network G with R(C,G) =
{∅}. (A cycle cluster in a network with |R(C,G)| > 0 will have the same or higher activation barrier for
any node in the cluster than the same cycle cluster in a network with R = {∅}. Since we are examining the
lower limit of Eq. 18, we consider the case with the lowest activation barrier. Any externally influenced
nodes cause ncrit to either increase or remain the same.) For any node i to be able to flip away from the
cancer state (although not necessarily remain there), we must have that hi = −aξ
c
i for a ≥ 0, meaning
that at least half of the nodes upstream of i must point away from the cancer state. The node i requiring
the smallest number of upstream nodes to be in the normal state is the node that satisfies deg−(i) = µ.
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Controlling less than µ/2 nodes will leave all uncontrolled nodes with a field in the cancer direction, and
no more flips will occur. Thus,
ncrit ≥
⌈µ
2
⌉
. (20)
For the upper limit of Eq. 18, consider a complete clique on N nodes, C = KN (that is, Aij = 1 for
all i, j ∈ V (KN ), including self loops) in a network G. First, let there be no connections to any nodes in
C from outside of C so that R(C,G) = {∅}. For odd N , forcing (N + 1)/2 nodes away from the cancer
state will result in the field
∑
j
Jijσj =
(
N − 1
2
−
N + 1
2
)
ξci = −ξ
c
i (21)
for all nodes i. After one time step, all nodes will flip away from the cancer state. For even N , forcing
N/2 nodes away from the cancer state will result in the field
∑
j
Jijσj =
(
N
2
−
N
2
)
ξci = 0 (22)
for all nodes i. At the next time step, the unfixed nodes will pick randomly between the normal and
cancer state. If at least one of these nodes makes the transition away from the cancer state, the field at all
other nodes will point away from the cancer direction. The system will then require one more time step
to completely settle to σi = −ξ
c
i . Thus, we have that for C = KN in a network G with R(C,G) = {∅},
ncrit(KN , G) =
⌈
N
2
⌉
. (23)
KN with σi(0) = ξ
c
i gives the largest activation barrier for any cycle cluster on N nodes with R(C,G) =
{∅} to switch away from the cancer attractor state. A general cycle cluster C with any topology on N
nodes with R(C,G) = {∅} in a network G will have deg−(i) ≤ N for all nodes i, and so we have the
upper bound
ncrit(C,G) ≤
⌈
N
2
⌉
, (24)
thus proving Eq. 18 for the special case of R(C,G) = {∅}.
Now consider a cycle cluster C on N nodes in a network G with |R(C,G)| ≥ 0. Suppose all nodes
in Zred(C,G) are fixed away from the cancer state. By Eq. 24, |Zred(C,G)| ≤ ⌈N/2⌉. For any node
12
i ∈ (R(C,G)∩Zred(C,G)), σi(t→∞) = −ξ
c
i is guaranteed because it has already been directly controlled.
Any node i ∈ (R(C,G) \ Zred(C,G)) has some incoming connections from nodes j /∈ V (C), and these
connections could increase the activation barrier enough such that fixing Zred(C,G) is not enough to
guarantee σi(t → ∞) = −ξ
c
i . To ensure that any node l ∈ V (C) points away from the cancer state, it
is sufficient to fix all nodes i ∈ (R(C,G) \ Zred(C,G)) as well as Zred(C,G) away from the cancer state.
This increases ncrit by at most |R(C,G) \ Zred(C,G)|, leaving
ncrit(C,G) ≤
⌈
N
2
⌉
+ |R(C,G) \ Zred(C,G)| . (25)
ncrit can never exceed N , however, because directly controlling every node results in controlling C. We
can thus say that
ncrit(C,G) ≤ min
(⌈
N
2
⌉
+ |R(C,G) \ Zred(C,G)|, N
)
. (26)
Finally, combining the upper limit in Eq. 26 with the lower limit from Eq. 20 gives Eq. 18. 
There can be more than one Zred for a given cycle cluster. Note that the tightest constraints on ncrit
in Eq. 18 come from using the Zred with the largest overlap with R. If finding Zred is too difficult, an
overestimate for the upper limit of ncrit can be made by assuming that R ∩ Zred = {∅} so that
⌈µ
2
⌉
≤ ncrit(C,G) ≤ min
(⌈
N
2
⌉
+ |R(C,G)| , N
)
. (27)
The cycle cluster in Fig. 5 has N = 9, R = {2, 9}, µ = 1, and one of the reduced sets of critical
nodes is Zred = {9, 10}, so 1 ≤ ncrit ≤ 6. It can be shown through an exhaustive search that for this
network ncrit = 2, and the set of critical nodes is Z = {9, 10} (see Fig. 6). Here, Z = Zred, although this
is not always the case. Because the cycle cluster has 9 nodes and 1 ≤ ncrit ≤ 6, at most
∑6
n=1
(
9
n
)
= 465
simulations are needed to find at least one solution for Z(C,G). However, the maximum number of
simulations required to find Z(C,G) increases exponentially and for larger networks the problem quickly
becomes intractable.
One heuristic strategy for controlling cycle clusters is to look for size k′ < |V (C)| bottlenecks inside
of C. Bottlenecks of size k ≫ 1 and average indegree 〈deg−(B)〉 ≪ k can contain high impact size k′
bottlenecks, where k′ < k. Size k ≥ 1 bottlenecks need to be compared to find the best set of nodes to
target to reduce mc
∞
. Simply comparing the impact is insufficent because a cycle cluster with a large
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impact could also have a large ncrit, requiring much more effort than its impact merits. Define the critical
efficiency of a bottleneck B as
ecrit(B) =
I(B)
ncrit(B,G)
. (28)
If the critical efficiency of a cycle cluster is much smaller than the impacts of size 1 bottlenecks from
outside of the cycle cluster, the the cycle cluster can be safely ignored.
For some cycle clusters, however, not all of the nodes need to be controlled in order for a large portion
of the nodes in the cycle cluster’s control set to flip. Define the optimal efficiency of a bottleneck B as
eopt(B) = max
n=1,2,...
(
I (
⋃n
i=1Bi)
n
)
(29)
where Bi ⊆ V (B) are size 1 bottlenecks and I(Bi) > I(Bi+1) for all i. Note that for any size 1 bottleneck
B, eopt(B) = ecrit(B) = I(B). This quantity thus allows bottlenecks with very different properties (I(B),
ncrit(B,G), or |V (B)|) to be ranked against each other.
All strategies presented above are designed to select the best individual or small group of nodes
to target. Significant changes in the biological networks’ magnetization require targeting many nodes,
however. Brute force searches on the effect of larger combinations of nodes are typically impossible
because the required number of simulations scales exponentially with the number of nodes. A crude
Monte Carlo search is also numerically expensive, since it is difficult to sample an appreciable portion of
the available space. One alternative is to take advantage of the bottlenecks that can be easily found, and
rank all size k ≥ 1 bottlenecks Bi in an ordered list U such that
U = (B1, B2, B3, . . .) (30)
where
eopt(Bi) ≥ eopt(Bi+1) , Bi 6⊂ L(Bj) (31)
for all Bi, Bj ∈ U and fix the bottlenecks in the list in order. This is called the efficiency-ranked strategy.
If all size k > 1 bottlenecks are ignored, it is called the pure efficiency-ranked strategy, and if size k > 1
bottlenecks are included it is called the mixed efficiency-ranked strategy.
An effective polynomial-time algorithm for finding the top z nodes to fix, which we call the best+1
strategy (equivalent to a greedy algorithm), works as follows: (1) Begin with a seed set of nodes to fix,
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F ; (2) Test the effect of fixing F ∪ i for all allowed nodes i /∈ F ; (3) F ← F ∪ ibest, where ibest is the best
node from all i sampled; (4) If |F | < z, go to step (2). Otherwise, stop. The seed set of nodes could be
the single highest impact size 1 bottleneck in the network, or it could be the best set of n nodes (where
n < z) found from a brute force search.
Cancer Signaling
In application to biological systems, we assume that the magnetization of cell type a is related to the
viability of cell type a, that is, the fraction of cells of type a that survives a drug treatment. It is
reasonable to assume that the viability of cell type a, va(ma
∞
), is a monotonically increasing function
of ma
∞
. Because the exact relationship is not known, we analyze the effect of external perturbations in
terms of the final magnetizations.
We need to use as few controllers as possible to sufficiently reduce mc
∞
while leaving mn
∞
≈ +1. In
practical applications, however, one is limited in the set of druggable targets. All classes of drugs are
constrained to act only on a specific set of biological components. For example, one class of drugs that
is currently under intense research is protein kinase inhibitors [16]. In this case one has two constraints:
the only nodes that can be targeted are those that correspond to kinases, and they can only be inhibited,
i.e. turned off. We will use the example of kinase inhibitors to show how control is affected by such
types of constraints. In the real systems studied, many differential nodes have only similarity nodes
upstream and downstream of them, while the remaining differential nodes form one large cluster. This
is not important for p = 1, but the effective edge deletion for p = 2 results in many islets, which are
nodes i with Aij = Aji = 0 for all i 6= j (self-loops allowed). Controlling islets requires targeting each
islet individually. For p = 2, we concentrate on controlling only the largest weakly connected differential
subnetwork. All final magnetizations are normalized by the total number of nodes in the full network,
even if the simulations are only conducted on small portion of the network.
The data files for all networks and attractors analyzed below can be found in Supplementary Infor-
mation.
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Lung Cell Network
The network used to simulate lung cells was built by combining the kinase interactome from Phospho-
POINT [72] with the transcription factor interactome from TRANSFAC [47]. Both of these are general
networks that were constructed by compiling many observed pairwise interactions between components,
meaning that if j → i, at least one of the proteins encoded by gene j has been directly observed interacting
with gene i in experiments. This bottom-up approach means that some edges may be missing, but those
present are reliable. Because of this, the network is sparse (∼ 0.057% complete, see Table 2), resulting in
the formation of many islets for p = 2. Note also that this network presents a clear hierarchical structure,
characteristic of biological networks [30,56], with many ”sink” nodes [61] that are targets of transcription
factors and a relatively large cycle cluster originating from the kinase interactome.
It is important to note that this is a non-specific network, whereas real gene regulatory networks can
experience a sort of “rewiring” for a single cell type under various internal conditions [46]. In this analysis,
we assume that the difference in topology between a normal and a cancer cell’s regulatory network is
negligible. The methods described here can be applied to more specialized networks for specific cell types
and cancer types as these networks become more widely avaliable.
In our signaling model, the IMR-90 cell line [51, 52] was used for the normal attractor state, and the
two cancer attractor states examined were from the A549 (adenocarcinoma) [37, 53, 60, 63, 68] and NCI-
H358 (bronchioalveolar carcinoma) [63, 68] cell lines. Gene expression measurements from all referenced
studies for a given cell line were averaged together to create a single attractor. The resulting magnetization
curves for A549 and NCI-H358 are very similar, so the following analysis addresses only A549. The full
network contains 9073 nodes, but only 1175 of them are differential nodes in the IMR-90/A549 model.
In the unconstrained p = 1 case, all 1175 differential nodes are candidates for targeting. Exhaustively
searching for the best pair of nodes to control requires investigating 689725 combinations simulated on
the full network of 9073 nodes. However, 1094 of the 1175 nodes are sinks (i.e. nodes i with outdegree
deg+(i) = 0, ignoring self loops) and therefore have I(i) = eopt(i) = 1, which can be safely ignored.
The search space is thus reduced to 81 nodes, and finding even the best triplet of nodes exhaustively is
possible. Including constraints, only 31 nodes are differential kinases with ξci = +1. This reduces the
search space at the cost of increasing the minimum achievable mc
∞
.
There is one important cycle cluster in the full network, and it is composed of 401 nodes. This cycle
cluster has an impact of 7948 for p = 1, giving a critical efficiency of at least ∼ 19.8, and 1 ≤ ncrit ≤ 401
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by Eq. 27. The optimal efficiency for this cycle cluster is eopt = 29, but this is achieved for fixing the
first bottleneck in the cluster. Additionally, this node is the highest impact size 1 bottleneck in the full
network, and so the mixed efficiency-ranked results are identical to the pure efficiency-ranked results for
the unconstrained p = 1 lung network. The mixed efficiency-ranked strategy was thus ignored in this
case.
Fig. 7 shows the results for the unconstrained p = 1 model of the IMR-90/A549 lung cell network.
(All simulations were performed using MATLAB on a desktop computer. Running the simulations to
make all curves shown below required approximately 12 hours.) The unconstrained p = 1 system has
the largest search space, so the Monte Carlo strategy performs poorly. The best+1 strategy is the most
effective strategy for controlling this network. The seed set of nodes used here was simply the size
1 bottleneck with the largest impact. Note that best+1 works better than effeciency-ranked. This is
because best+1 includes the synergistic effects of fixing multiple nodes, while efficiency-ranked assumes
that there is no overlap between the set of nodes downstream from multiple bottlenecks. Importantly,
however, the efficiency-ranked method works nearly as well as best+1 and much better than Monte Carlo,
both of which are more computationally expensive than the efficiency-ranked strategy.
Fig. 8 shows the results for the unconstrained p = 2 model of the IMR-90/A549 lung cell network.
The search space for p = 2 is much smaller than that for p = 1. The largest weakly connected differential
subnetwork contains only 506 nodes (see Table 3) , and the remaining differential nodes are islets or are in
subnetworks composed of two nodes and are therefore unnecessary to consider. Of these 506 nodes, 450
are sinks. Fig. 9 shows the largest weakly connected component of the differential subnetwork, and the
top five bottlenecks in the unconstrained case are shown in red. If limiting the search to differential kinases
with ξci = +1 and ignoring all sinks, p = 2 has 19 possible targets. There is only one cycle cluster in
the largest differential subnetwork, containing 6 nodes. Like the p = 1 case, the optimal efficiency occurs
when targeting the first node, which is the highest impact size 1 bottleneck. Because the mixed efficiency-
ranked strategy gives the same results as the pure efficiency-ranked strategy, only the pure strategy was
examined. The Monte Carlo strategy fares better in the unconstrained p = 2 case because the search
space is smaller. Additionally, the efficiency-ranked strategy does worse against the best+1 strategy for
p = 2 than it did for p = 1. This is because the effective edge deletion decreases the average indegree
of the network and makes nodes easier to control indirectly. When many upstream bottlenecks are
controlled, some of the downstream bottlenecks in the efficiency-r
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Thus, controlling these nodes directly results in no change in the magnetization. This gives the plateaus
shown for fixing nodes 9-10 and 12-15, for example.
The only case in which an exhaustive search is possible is for p = 2 with constraints, which is
shown in Fig. 10. Note that the polynomial-time best+1 strategy identifies the same set of nodes as
the exponential-time exhaustive search. This is not surprising, however, since the constraints limit the
available search space. This means that the Monte Carlo also does well. The efficiency-ranked method
performs worst. The efficiency-ranked strategy is designed to be a heuristic strategy that scales gently,
however, and is not expected to work well in such a small space when compared with more computationally
expensive methods.
B Cell Network
The B cell network was derived from the B cell interactome of Ref. [43]. The reconstruction method
used in Ref. [43] removes edges from an initially complete network depending on pairwise gene expression
correlation. Additionally, the original B cell network contains many protein-protein interactions (PPIs) as
well as transcription factor-gene interactions (TFGIs). TFGIs have definite directionality: a transcription
factor encoded by one gene affects the expression level of its target gene(s). PPIs, however, do not have
obvious directionality. We first filtered these PPIs by checking if the genes encoding these proteins
interacted according to the PhosphoPOINT/TRANSFAC network of the previous section, and if so, kept
the edge as directed. If the remaining PPIs are ignored, the results for the B cell are similar to those of
the lung cell network. We found more interesting results when keeping the remaining PPIs as undirected,
as is discussed below.
Because of the network construction algorithm and the inclusion of many undirected edges, the B
cell network is more dense (∼0.290% complete, see Table 2) than the lung cell network. This higher
density leads to many more cycles than the lung cell network, and many of these cycles overlap to
form one very large cycle cluster containing ∼66% of nodes in the full network. All gene expression
data used for B cell attractors was taken from Ref. [17]. We analyzed two types of normal B cells
(na¨ıve and memory) and three types of B cell cancers (diffuse large B-cell lymphoma (DLBCL), follicular
lymphoma, and EBV-immortalized lymphoblastoma), giving six combinations in total. We present results
for only the na¨ıve/DLBCL combination below, but Tables 3 and 4 list the properties of all normal/cancer
combinations. Again, all gene expression measurements for a given cell type were averaged together to
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produce a single attractor. The full B cell network is composed of 4364 nodes. For p = 1, there is one
cycle cluster C composed of 2886 nodes. This cycle cluster has 1 ≤ ncrit(C) ≤ 1460, I(C) = 4353, and
3.0 ≤ ecrit(C) ≤ 4353. Finding Z(C) was deemed too difficult.
Fig.11 shows the results for the unconstrained p = 1 case. Again, the pure efficiency-ranked strategy
gave the same results as the mixed efficiency-ranked strategy, so only the pure strategy was analyzed. As
shown in Fig. 11, the Monte Carlo strategy is out-performed by both the efficiency-ranked and best+1
strategies. The synergistic effects of fixing multiple bottlenecks slowly becomes apparent as the best+1
and efficiency-ranked curves separate.
Fig. 12 shows the results for the unconstrained p = 2 case. The largest weakly connected subnetwork
contains one cycle cluster with 351 nodes, with 1 ≤ ncrit ≤ 208. Although finding a set of critical nodes
is difficult, the optimal efficiency for this cycle cluster is 62.2 for fixing 10 bottlenecks in the cycle cluster.
This makes targeting the cycle cluster worthwhile. The efficiency of this set of 10 nodes is larger than
the efficiencies of the first 10 nodes from the pure efficiency-ranked strategy, so the mc
∞
from the mixed
strategy drops earlier than the pure strategy. Both strategies quickly identify a small set of nodes capable
of controlling a significant portion of the differential network, however, and the same result is obtained
for fixing more than 10 nodes. The best+1 strategy finds a smaller set of nodes that controls a similar
fraction of the cycle cluster, and fixing more than 7 nodes results in only incremental decreases in mc
∞
.
The Monte Carlo strategy performs poorly, never finding a set of nodes adequate to control a significant
fraction of the nodes in the cycle cluster.
Conclusion
Signaling models for large and complex biological networks are becoming important tools for designing
new therapeutic methods for complex diseases such as cancer. Even if our knowledge of biological
networks is incomplete, rapid progress is currently being made using reconstruction methods that use
large amounts of publicly available omic data [22,34]. The Hopfield model we use in our approach allows
mapping of gene expression patterns of normal and cancer cells into stored attractor states of the signaling
dynamics in directed networks. The role of each node in disrupting the network signaling can therefore be
explicitly analyzed to identify isolated genes or sets of strongly connected genes that are selective in their
action. We have introduced the concept of size k bottlnecks to identify such genes. This concept led to the
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formulation of several heuristic strategies, such as the efficiency-ranked and best+1 strategy to find nodes
that reduce the overlap of the cell network with a cancer attractor. Using this approach, we have located
small sets of nodes in lung and B cancer cells which, when forced away from their initial states with
local magnetic fields (representing targeted drugs), disrupt the signaling of the cancer cells while leaving
normal cells in their original state. For networks with few targetable nodes, exhaustive searches or Monte
Carlo searches can locate effective sets of nodes. For larger networks, however, these strategies become
too cumbersome and our heuristic strategies represent a feasible alternative. For tree-like networks, the
pure efficiency-ranked strategy works well, whereas the mixed efficiency-ranked strategy could be a better
choice for networks with high-impact cycle clusters.
We make two important assumptions in applying this analysis to real biological systems. First, we
assume that genes are either fully off or fully on, with no intermediate state. Modelling the state of a
neuron as “all-or-none” has long been accepted as a reasonable assumption [48], which provided the spin
glass framework for the Hopfield model. While similar switch-like behavior in gene regulatory networks
has been proposed as an explanation of, for example, segmentation in Drosophila embryos [39], assigning
a Boolean value to gene expression may be overly simplistic in many cases. A model which uses spins with
more than two projections could prove to be more realistic and predictive. Second, we assume that all
nodes update their status with a single timescale and with a single interaction strength. If the signaling
timescale τij for each edge in the biological network is known, simulations could be conducted in which
a signal traveling along an edge (j, i) reaches its target after τij time steps. This would amount to a
synchronous update schedule with a “queue” of signals moving between nodes. Likewise, our model gives
equal weight to all edges (aside from edges that are effectively deleted in the p = 2 case), whereas real
gene regulatory networks exhibit a spectrum of interaction strengths. This can easily be integrated with
our model by using a weighted, directed adjacency matrix. However, doing this would surely require a
change in control strategy.
Despite these issues, our model shows promise. Some of the genes identified in Table 4 are consistent
with current clinical and cancer biology knowledge. For instance, in the lung cancer list we found a well
known tumor suppressor gene (TP53) [10] that is frequently mutated in many cancer types including
lung cancer [65]. Mutations in PBX1 have recently been detected in non-small-cell lung cancer and this
gene is now being considered as a target for therapy and prognosis [49]. MAP3K3 and MAP3K14 are
in the MAPK/ERK pathway which is a target of many novel therapeutic agents [50], and SRC is a well
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known oncogene and a candidate target in lung cancer [59]. BCL6 (B-cell lymphoma 6) is the most
common oncogene in DLBCL, and it is known that its expression can predict prognosis and response to
drug therapy [33, 58, 71]. BCL6 is also frequently mutated in follicular lymphoma [2, 24]. Our analysis
identified BCL6 as an important drug target for both DLBCL and follicular lymphoma using either
naive or memory B-cells as a control for both p = 1 and p = 2. RBL2 disregulation has been recently
associated with many types of lymphoma [21,54,70]. FOXM1 is a potential therapeutic target in mature
B cell tumors [66] and ATF2 has been recently found to be highly disregulated in lymphoma [67, 69].
Besides BCL6 discussed above, the N/D list for DLBCL contains genes (MEF2A [9], NCOA1 [26, 73],
TGIF1 [11,32,44], NFATC3 [31]) that are all known to have a functional role in cancer, even if they have
not been associated to the specific B-cell cancer types we have considered. Our predictions are for the
immortalized cell lines we have selected, some of which are commonly used for in-vitro testing in many
laboratories. RNAi and targeted drugs could then be used in these cell lines against the top scoring
genes in Table 4 to test the disruption of survival or proliferative capacity. If experimentally validated,
our analysis based on attractor states and bottlenecks could be applied to patient-derived cancer cells by
integrating in the model patient gene expression data to identify patient-specific targets.
The above unconstrained searches assume that there exists some set of “miracle drugs” which can turn
any gene “on” and “off” at will. This limitation can be patially taken into account by using constrained
searches that limit the nodes that can be addressed. However, even the constrained search results are
unrealistic, since most drugs directly target more than one gene. Inhibitors, for example, could target
differential nodes with ξci = −1 and ξ
n
i = +1, which would damage only normal cells. Additionally, drugs
would not be restricted to target only differential nodes, and certain combinations could be toxic to both
normal and cancer cells. Few cancer treatments involve the use of a single drug, and the synergistic effects
of combining multiple drugs adds yet another level of complication to finding an effective treatment [28].
On the other hand, the intrinsic nonlinearity of a cellular signaling network, with its inherent structure
of attractor states, enhances control [18] so that a properly selected set of druggable targets might be
sufficient for robust control.
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Tables
Symbol Explanation
G Set of nodes and directed edges (network)
N Number of nodes
Aij Adjacency matrix
V (G) Set of nodes in G
E(G) Set of edges in G
deg+/−(i) Outdegree/indegree of node i
σi Spin of node i, = ±1
ξa ath attractor
ξn/c Normal/cancer attractor
Jij Coupling matrix
hi Total field at node i
hexti External field applied to node i
T Temperature
Q Set of source and effective source nodes
ma(t) Magnetization along attractor a at time t
ma
∞
Steady-state magnetization along attractor a
p Number of attractors in coupling matrix
S Set of similarity nodes
D Set of differential nodes
L(B) Control set of bottleneck B
I(B) Impact of bottleneck B
C Cycle cluster
B Size k bottleneck, where k = |B|
Z(B,G) Set of critical nodes for bottleneck B in network G
ncrit(B,G) Critical number of nodes in bottleneck B in network G
R(C,G) Set of externally influenced nodes
W (C,G) Set of intruder connections
Zred(C,G) Reduced set of critical nodes
µ Minimum indegree of all nodes in a cycle cluster
ecrit(B) Critical efficiency of bottleneck B
eopt(B) Optimal efficiency of bottleneck B
Table 1. Reference table for symbols. This table lists all important symbols introduced in the
article with a brief explanation of its purpose.
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Properties Lung B cell
Nodes 9073 4364
Edges 45635 55144
Sources 129 8
Sinks 8443 1418
Av. outdegree 5.03 12.64
Max outdegree 240 2372
Max indegree 68 196
Self-loops 238 0
Undirected edges 350 23386
Diameter 11 11
Max cycle cluster 401 2886
Av. clustering coeff. [27] 0.0544 0.2315
Table 2. General properties of the full networks. The network used for the analysis of lung
cancer is a generic one obtained combining the data sets in Refs. [72] and [47]. The B cell network is a
curated version of the B cell interactome obtained in Ref. [43] using a network reconstruction method
and gene expression data from B cells.
Properties
Lung B
I/A I/H N/D N/F N/L M/D M/F M/L
Nodes 506 667 684 511 841 621 457 742
Edges 846 1227 2855 1717 3962 2525 1501 3401
Sources and effective sources 30 34 12 11 9 9 9 12
Sinks and effective sinks 450 598 286 198 369 275 204 333
Av. outdegree 1.67 1.84 4.17 3.36 4.71 4.07 3.28 4.58
Max outdegree 52 51 155 143 336 138 132 292
Max indegree 8 10 40 29 49 35 27 44
Self-loops 27 31 0 0 0 0 0 0
Undirected edges 0 4 1238 738 1468 1000 596 1214
Diameter 9 9 12 15 12 13 14 12
Max cycle cluster size 6 3 351 280 397 305 199 337
Av. clustering coeff 0.0348 0.0421 0.1878 0.1973 0.2446 0.1751 0.1935 0.2389
Table 3. Properties of the largest weakly connected differential subnetworks for all cell
types. I = IMR-90 (normal), A = A549 (cancer), H = NCI-H358 (cancer), N = Na¨ıve (normal), M =
Memory (normal), D = DLBCL (cancer), F = Follicular lymphoma (cancer), L = EBV-immortalized
lymphoblastoma (cancer).
Figure Legends
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I/A I/H
p = 1 p = 2 p = 1 p = 2
Gene I Gene I Gene I Gene I
UNC
HNF1A 29 OR5I1 35 HNF1A 29 HMX1 41
TMEM37 22 TMEM37 25 MAP3K3 18 PBX1 38
OR5I1 20 HNF1A 23 TP53 18 MYB 25
MAP3K14 19 POSTN 21 RUNX1 17 ITGB2 20
MAP3K3 18 RORA 18 RORA 16 TNFRSF10A 18
CON
MAP3K14 19 SRC 15 TTN 16 BMPR1B 18
SRC 14 BMPR1B 7 RIPK3 6 LCK 8
N/D N/F N/L
p = 1 p = 2 p = 1 p = 2 p = 1 p = 2
Gene I Gene I Gene I Gene I Gene I Gene I
UNC
BCL6 12 NFIC 22 BCL6 12 NCOA1 20 RBL2 11 RBL2 22
MEF2A 5 TGIF1 19 MEF2A 5 NFATC3 15 FOXM1 8 ATF2 12
NCOA1 5 BCL6 14 NCOA1 5 BCL6 11 ATF2 7 NFATC3 11
TGIF1 4 FOXJ2 12 TGIF1 4 CEBPD 8 RXRA 5 RXRA 9
NFATC3 4 NFATC3 12 NFATC3 4 RELA 8 NFATC3 4 PATZ1 8
CON
BUB1B 2 CSNK2A2 2 BUB1B 2 WEE1 2 BUB1B 2 PRKCD 2
AAK1 1 AKT1 2 AAK1 1 CSNK2A2 2 AAK1 1 AURKB 2
M/D M/F M/L
p = 1 p = 2 p = 1 p = 2 p = 1 p = 2
Gene I Gene I Gene I Gene I Gene I Gene I
UNC
BCL6 12 FOXJ2 12 BCL6 12 NCOA1 18 RBL2 11 RBL2 16
MEF2A 5 NFIC 12 MEF2A 5 BCL6 13 FOXM1 8 ATF2 10
NCOA1 5 BCL6 11 NCOA1 5 E2F3 9 ATF2 7 ZNF91 8
NFATC3 4 NCOA1 9 NFATC3 4 RUNX1 9 RXRA 5 STAT6 8
SMAD4 4 MEF2A 8 RELA 4 TFE3 7 TGIF1 4 FOXM1 8
CON
AAK1 1 RIPK2 1 AAK1 1 ROCK2 2 AAK1 1 AURKB 2
RIPK2 1 MAST2 1 RIPK2 1 RIPK2 1 SCYL3 1 RIPK2 1
Table 4. Best single genes and their impacts for the p=1 and p=2 models. The
unconstrained (UNC) and constrained (CON) case are shown. The constrained case refer to target that
are kinases and are expressed in the cancer case. I = IMR-90 (normal), A = A549 (cancer), H =
NCI-H358 (cancer), N = Na¨ıve (normal), M = Memory (normal), D = DLBCL (cancer), F = Follicular
lymphoma (cancer), L = EBV-immortalized lymphoblastoma (cancer).
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Figure 1. Network segregation for two attractor states (p = 2). Every edge that connects a
similarity node to a differential node or a differential node to a similarity node transmits no signal. This
means that the signaling in the right network shown above is identical to that of the left network.
Because the goal is to leave normal cells unaltered while damaging cancer cells as much as possible, all
similarity nodes can be safely ignored, and searches and simulations only need to be done on the
differential subnetwork.
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Figure 2. A directed acyclic network. Controlling all three source nodes (nodes 1, 2 and 3)
guarantees full control of the network, but are ineffective when targeted individually. The best single
node to control in this network is node 6 because it directly controls all downstream nodes.
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Figure 3. A network in which nodes 4, 5, 6 and 7 compose a single cycle cluster. The high
connectivity of node 4 prevents any changes made to the spin of nodes 1-3 from propagating
downstream. The only way to indirectly control nodes 8-10 is to target nodes inside of the cycle cluster.
Targeting node 4, 6 or 7 will cause the entire cycle cluster to flip away from its initial state,
guaranteeing control of nodes 4-10 (see Fig. 4).
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Figure 4. Cancer magnetization from targeting various nodes in the network shown in
Fig. 3, averaged over 10,000 runs. The averaging removes fluctuations due to the random flipping
of nodes with hi = 0. Targeting node 7 results in the quickest stabilization, but targeting any one of
nodes 4, 6 or 7 results in the same final magnetization.
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Figure 5. A network with a cycle cluster C, composed of nodes 2-10, that cannot be
controlled at T = 0 by controlling any single node. Here, the set of externally influenced nodes is
R(C,G) = {2, 9}, the set of intruder connections is W (C,G) = {(1, 2), (1, 9)}, the reduced set of critical
nodes is Zred(C,G) = {9, 10}, the minimum indegree is µ = 1 and the number of nodes in the cycle
cluster is N = 9. By Eq. 18, this gives the bounds of the critical number of nodes to be 1 ≤ ncrit ≤ 6.
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Figure 6. Magnetization for network from Fig. 5, averaged over 10,000 runs. There is no
single node to target that will control the cycle cluster, but fixing nodes 9 and 10 results in full control
of the cycle cluster, leaving only node 1 in the cancer state. This means Z(C,G) = {9, 10} and ncrit = 2.
Figure 7. Final cancer magnetizations for an unconstrained search on the lung cell
network using p = 1. The efficiency-ranked strategy outperforms the relatively expensive Monte
Carlo strategy. The best+1 strategy works best, although it requires the largest computational time.
Note that the mixed efficiency-ranked curve is not shown because it is identical to the pure
efficiency-ranked curve. Key for magnetization curves: MC = Monte Carlo, B+1 = best+1, ERP =
pure efficiency-ranked, ERM = mixed efficiency-ranked, EX = exhausive search.
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Figure 8. Final cancer magnetizations for an unconstrained search on the lung cell
network using p = 2. As in the p = 1 case, the efficiency-ranked strategy outperforms the expensive
Monte Carlo search. The plateaus in the efficiency-ranked strategy when fixing 9-10, 12-15, 20-21, etc.
nodes are a result of targeting bottlenecks that are already indirectly controlled.
Figure 9. Largest weakly connected differential subnetwork for IMR-90/A549 and p = 2.
Out of the 506 pictured nodes, 450 are sinks and therefore have an impact equal to one. The top five
bottlenecks are labeled with their gene names and colored orange.
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Figure 10. Final cancer magnetizations for a constrained search on the lung cell network
using p = 2. This is the only case in which a limited exhaustive search is possible. Interestingly, the
exhaustive search locates the same nodes as the best+1 strategy for fixing up to eight nodes. The
efficiency-ranked strategy performs poorly compared to the Monte Carlo strategy because the search
space is small and a large portion of the available space is sampled by the Monte Carlo search.
Figure 11. Final cancer magnetizations for an unconstrained search on the B cell network
using p = 1. The Monte Carlo strategy is ineffective for fixing any number of nodes. The
efficiency-ranked and best+1 curves slowly separate because synergistic effects accumulate faster for
best+1.
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Figure 12. Final cancer magnetizations for an unconstrained search on the B cell network
using p = 2. The rather sudden drop in the magnetization between controlling 5 and 10 nodes in the
efficiency-ranked strategies comes from flipping a significant portion of a cycle cluster. This is the only
network examined in which the mixed efficiency-ranked strategy produces results different from the
pure efficiency-ranked strategy.
